FIG. 3.

Mice receiving BM transfer during treatment with Ig-GAD2 display increased insulin-producing pancreatic β-cells. A: BGLs in mice grafted with insulin pellets and given BM (n = 8), Ig-GAD2 (n = 7), or Ig-GAD2+BM (n = 17). B: Representative hematoxylin-eosin staining (100×) of pancreatic sections from mice recipient of BM, Ig-GAD2, or Ig-GAD2+BM (killed on day 70) (n = 6 per group). Unmanipulated 4- to 6-week-old healthy (BGL ≤140 mg/dL), hyperglycemic (BGL = 160–250 mg/dL), and recent-onset diabetic (BGL ≥300 mg/dL) mice are included as control. C: Islet infiltration severity scores of the indicated groups. D: Representative immunohistochemistry staining (100×) for insulin (brown) with nuclei counterstained with hematoxylin-eosin (blue). E: Quantification of insulin⁺ cells per islet. F: Number of islets that contain >10 insulin⁺ cells. G: Mass of β-cells. Results in E–G are based on the analysis of three to six nonserial sections per pancreas for six mice in each group. Specifically, at least 60 islets were counted for each of the new-onset diabetic, BM-treated, or Ig-GAD2–treated groups of mice. For the hyperglycemic and Ig-GAD2+BM–treated groups, at least 300 islets were counted per group. Error bars, mean ± SEM. *P < 0.05; **P < 0.01.